<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1753">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 07, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03325556</url>
  </required_header>
  <id_info>
    <org_study_id>ACP-103-045</org_study_id>
    <secondary_id>2017-002227-13</secondary_id>
    <nct_id>NCT03325556</nct_id>
  </id_info>
  <brief_title>Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ACADIA Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ACADIA Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of pimavanserin compared with placebo
      in preventing a relapse of psychotic symptoms in subjects with dementia who have psychosis
      and who were stabilized after 8-12 weeks open label pimavanserin treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2017</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from randomization to relapse in the double-blind period</measure>
    <time_frame>Up to 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to discontinuation from the double-blind period for any reason</measure>
    <time_frame>Up to 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">356</enrollment>
  <condition>Dementia-related Psychosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug - Pimavanserin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, tablets, once daily by mouth</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimavanserin 34 mg</intervention_name>
    <description>Pimavanserin 34 mg total daily dose, tablets, once daily by mouth</description>
    <arm_group_label>Drug - Pimavanserin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimavanserin 20 mg</intervention_name>
    <description>Pimavanserin 20 mg total daily dose, tablets, once daily by mouth</description>
    <arm_group_label>Drug - Pimavanserin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meets criteria for All-cause Dementia according to NIA-AA guidelines

          2. Meets clinical criteria for one of the following disorders: Dementia associated with
             Parkinson's disease, Dementia with Lewy bodies, Possible or probable Alzheimer's
             disease, Frontotemporal degeneration spectrum disorders, Vascular dementia

          3. Has an MMSE score ≥6 and ≤24

          4. Has had psychotic symptoms for at least 2 months

          5. Must be on a stable does of cholinesterase inhibitor or memantine, if applicable

          6. If the subject is female, she must be of non-childbearing potential or must agree to
             use a clinically acceptable method of contraception for the duration of the study

        Exclusion Criteria:

          1. Has psychotic symptoms that are primarily attributable to a condition other than
             dementia

          2. Has had a recent major depressive episode

          3. Has experienced suicidal ideation or behavior within 3 months prior to study
             enrollment

          4. Has evidence of a non-neurologic medical comorbidity or medication use that could
             substantially impair cognition

          5. Has a history of ischemic stroke within the last 12 months or any evidence of
             hemorrhagic stroke

          6. Has a known history of cerebral amyloid angiopathy (CAA), epilepsy, CNS neoplasm, or
             unexplained syncope

          7. Has greater than New York Heart Association (NYHA) Class 2 congestive heart failure or
             Class 2 angina pectoris, sustained ventricular tachycardia, ventricular fibrillation,
             or torsade de pointes, or syncope due to an arrhythmia

          8. Had a myocardial infarction within the last 6 months

          9. Has a known personal or family history or symptoms of long QT syndrome

         10. Has a significant unstable medical condition that could interfere with subject's
             ability to complete the study or comply with study procedures

         11. Requires treatment with a medication or other substance that is prohibited by the
             protocol

        Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to
        ensure that all criteria for study participation are met.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Scott Stubbe</last_name>
    <phone>858-261-2968</phone>
    <email>sstubbe@acadia-pharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Siobhan Shawbell</last_name>
    <phone>858-366-6207</phone>
    <email>sshawbell@acadia-pharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ATP Clinical Research Inc.</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Associated Neurologists, P.C.</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research Institute, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Collier Neurologic Specialists LLC</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Research Group of Central Florida</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alzheimer Disease Center</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <zip>02169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BioBehavioral Health</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurological Associates of Albany, PC</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Abington Neurological Associates Ltd.</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- Old date names will be dropped in a few months (sometime in 2018)                        -->
  <lastchanged_date>October 25, 2017</lastchanged_date>
  <firstreceived_date>October 18, 2017</firstreceived_date>
  <!-- New date names                                                                           -->
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <!-- End of dates                                                                             -->
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dementia</keyword>
  <keyword>Dementia-related psychosis</keyword>
  <keyword>Dementia associated with Parkinson's disease</keyword>
  <keyword>Dementia with Lewy bodies</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Behavioral variant frontotemporal dementia</keyword>
  <keyword>Progressive supranuclear palsy</keyword>
  <keyword>Corticobasal degeneration</keyword>
  <keyword>Vascular dementia</keyword>
  <keyword>Hallucinations</keyword>
  <keyword>Delusions</keyword>
  <keyword>Psychosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Hallucinations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimavanserin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

